MediWound’s NexoBrid® to be Highlighted in Presentations at the American Burn Association 48th Annual Meeting

YAVNE, Israel, May 02, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that 11 presentations highlighting the positive results achieved by clinicians using NexoBrid® as an effective enzymatic debridement for severe burns will be presented during the American Burn Association (ABA) 48th Annual Meeting, taking place May 3-6, 2016 at Caesars Palace in Las Vegas.

“We are thrilled to have burn specialists from across Europe and Israel sharing their hands-on experience with NexoBrid at the ABA meeting before a global audience of their peers. The large number of presentations being presented this year reflects the growing number of physicians treating ever-increasing numbers of patients with NexoBrid. We are grateful the collective experience of European and Israeli burn specialists has continued to elucidate how NexoBrid can contribute to the further advancement of burn care,” said Gal Cohen, President and Chief Executive Officer of MediWound.

The following data highlighting NexoBrid will be presented during the ABA meeting:

Title: “Burn Depth Assessment: Laser Doppler Imaging (LDI) vs. Enzymatic Debridement”
Authors: S. Monstrey, MD, PhD, J. Verbelen, RN, H. Hoeksema, PT
Ghent University Hospital, Ghent, Belgium
Date/Time: May 5th from 11:15 a.m. – 11:30 a.m.
Title: “Healing of the Wound Bed after Selective Enzymatic Debridement”
Authors: S. Monstrey, MD, PhD, Y. Shoham, MD, Y. Krieger, MD, E. Silberstein, MD, A. Bogdanov-Berezovsky, MD, L. Rosenberg, MD
Ghent University Hospital, Ghent, Belgium; Department of Plastic & Reconstructive Surgery and Burn Unit, Soroka University Medical Center, Beer Sheva, Israel
Date/Time:May 5th from 12:30 p.m. – 1:30 p.m.
Title: “Early Enzymatic Debridement of Deep Dermal Burns - Results in Acute Wound Healing and Long-Term Follow up Examinations After 70 Treatments”
Authors: A. Schulz, MD, W. Perbix, MD, P. Fuchs, MD, E. Demir, MD, I. Rothermund, MD, J. Schiefer, MD
Clinic Cologne Merheim Campus of the Private University Witten/Herdecke, Cologne, Germany
Date/Time: May 5th from 12:30 p.m. – 1:30 p.m.
Title: “Early Enzymatic Debridement of Deep Dermal Facial Burns - Results in Acute Healing and Long-Term Scar Quality Compared to Surgical Treatment”
Authors: A. Schulz, MD, W. Perbix, MD, P. Fuchs, MD, I. Rothermund, MD, E. Demir, MD, J. Schiefer, MD
Clinic Cologne Merheim Campus of the Private University Witten/Herdecke, Cologne, Germany
Date/Time: May 5th from 12:30 p.m. – 1:30 p.m.
Title:“Bromelain Based Enzymatic Eschar Removal: Assimilation of a New Technology by a National Burn Care System”
Authors: I. Mataro, MD, E. Caleffi, MD, R. D'Alessio, MD, A. Di Castri, MD, A. Di Lonardo, MD, G. Maggio, MD, M. Palombo, MD, A. Posadinu, MD, R. Ranno, MD
Cardarelli Hospital, Naples, Italy; Civile Maggiore Hospital, Parma, Italy; University of Pisa Burn Center, Pisa, Italy; University of Bari Burn Center, Bari, Italy; Sant'Eugenio Hospital, Rome, Italy; SS Annunziata Hospital, Sassari, Italy; Cannizzaro Hospital, Catania, Italy
Date/Time: May 5th from 12:30 p.m. – 1:30 p.m.
Title: “Burn and NexoBrid™: Our Experience”
Authors:M. Palombo Sr., MD, G. Delli Santi, MD, S. Moroni, MD, T. Anniboletti, MD, C. Maestrini, MD, M. Cempanari, MD, M. Floris, MD, P. Carnì, MD, P. Palombo, MD, PhD
Sant'Eugenio Hospital, Rome, Italy
Date/Time: May 4th from 12:30 p.m. – 1:30 p.m.
Title: “Enzymatic Debridement as a Non-Traumatic Alternative for Safe Early Escharectomy”
Authors: B. Presman, MD, I. Tocco-Tussardi, MD, R. Heedman, MS, F. Huss, MD
Uppsala Burn Centre, Uppsala, Sweden
Date/Time:May 4th from 12:30 p.m. – 1:30 p.m.
Title: “Implementation of a Medical Training Program for the Introduction of a New Enzymatic Eschar Removal Agent”
Authors: Y. Shoham, MD, L. Rosenberg, MD
Soroka University Medical Center, Beer Sheva, Israel; Meir Medical Center, Kfar Saba, Israel
Date/Time: May 5th from 12:30 p.m. – 1:30 p.m.
Title: “Bromelain Based Enzymatic Debridement, Negative Pressure Wound Therapy and Full Thickness Burns: Results of a Pig Study”
Authors: Y. Shoham, MD, F. Sander, MD, L. Rosenberg, MD
Soroka University Medical Center, Beer Sheva, Israel; Unfallkrankenhaus Berlin, Berlin, Germany; Meir Medical Center, Kfar Saba, Israel
Date/Time: May 5th from 12:30 p.m. – 1:30 p.m.
Title:“Early Debridement of Sulfur Mustard Contaminated Skin by Bromelain Based Debriding Means: Results of a Concept Validation Pig Model Study”
Authors: L. Rosenberg, MD, Y. Shoham, MD, D. Geblinger, PhD, E. Asculai, PhD
Meir Medical Center, Kfar Saba, Israel; Soroka University Medical Center, Beer Sheva, Israel; MediWound Ltd, Yavne, Israel
Date/Time: May 5th from 12:30 p.m. – 1:30 p.m.
Title: “Bromelain Based Enzymatic Debridement of Chronic Wounds: Preliminary Results”
Authors: L. Rosenberg, MD, Y. Shoham, MD, E. Tamir, MD, N. Rosenberg, MD, A. Shalom, MD
Meir Medical Center, Kfar Saba, Israel; Soroka University Medical Center, Beer Sheva, Israel; Macabi Health Services, Tel Aviv, Israel
Date/Time:May 5th from 12:30 p.m. – 1:30 p.m.

About the American Burn Association

The American Burn Association and its members dedicate their efforts and resources to promoting and supporting burn-related research, education, care, rehabilitation, and prevention. The ABA has more than 3,500 members in the United States, Canada, Europe, Asia, and Latin America. Members include physicians, nurses, occupational and physical therapists, researchers, social workers, firefighters, and hospitals with burn centers. The ABA’s multidisciplinary membership enhances its ability to work toward common goals with other organizations on educational programs.

About NexoBrid

NexoBrid is an easy-to-use, topically-applied product that removes dead or damaged tissue, known as eschar, in approximately four hours without harming the surrounding healthy tissues. NexoBrid received marketing authorization from the European Medicines Agency for the removal of eschar in adults with deep partial and full-thickness thermal burns, is commercially available in Europe and Israel and will be launched in Argentina in the coming months. Representing a new paradigm in burn care management, NexoBrid demonstrated in clinical studies, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier than other modalities, without harming viable tissues. The removal of eschar or “debridement” is a critical first step in the successful healing of severe burns and chronic and other hard-to-heal wounds. With the current standard of care, burn eschar is removed either with existing topical agents that have been found to be minimally effective or that take a significantly longer period of time to work, or by resorting to non-selective surgery, which is traumatic and may result in loss of blood and viable tissue necessitating further surgical treatments. The U.S. Phase 3 clinical trial and registration process for NexoBrid is being funded in whole or in part with federal funds under a contract with the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority.

About MediWound Ltd.

MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe and Israel, with plans for a launch in Argentina. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissues.

MediWound's second innovative product, EscharEx® is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx® contains the same proteolytic enzyme technology as NexoBrid®, and benefits from the wealth of existing development data on NexoBrid®. In two Phase 2 studies, EscharEx® has demonstrated safety and efficacy in the debridement of chronic and other hard-to-heal wounds, within a few daily applications. For more information, please visit www.mediwound.com.

Contacts: Sharon Malka Chief Financial and Operations Officer MediWound ir@mediwound.co.il Anne Marie Fields Senior Vice President LHA 212-838-3777 afields@lhai.com

Source:MediWound Ltd.